At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
armodafinil +3 moredrug
Likely dose
armodafinil 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia
In Brief
A Phase 2 clinical trial evaluating armodafinil and placebo for Schizophrenia. Completed, enrolled 60 participants across 12 sites.
Detailed Summary
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartJul 2007
Primary CompletionDec 2007
TodayJul 2026
First PostedJun 19, 2007
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 19.0 years ago
Interventions
armodafinildrug
50 mg/day armodafinil
armodafinildrug
100 mg/day armodafinil
armodafinildrug
200 mg/day armodafinil
placebodrug
placebo